Statins and Brain Health

Alzheimer's Disease and Cerebrovascular Disease Biomarkers in Older Adults

Vijay K. Ramanan, Scott A. Przybelski, Jonathan Graff-Radford, Anna M. Castillo, Val Lowe, Michelle M Mielke, Rosebud O Roberts, Robert I. Reid, David S Knopman, Clifford R Jr. Jack, Ronald Carl Petersen, Prashanthi D Vemuri

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Statins have been proposed to reduce the risk of Alzheimer's disease (AD). Objective: Assess whether long-term statin use was associated with neuroimaging biomarkers of aging and dementia. Methods: We analyzed neuroimaging biomarkers in 1,160 individuals aged 65+ from the Mayo Clinic Study of Aging, a population-based prospective longitudinal study of cognitive aging. Results: Statin-treated (5+ years of therapy) individuals had greater burden of mid-and late-life cardiovascular disease (p < 0.001) than statin-untreated (=3 months) individuals. Lower fractional anisotropy in the genu of the corpus callosum, an early marker of cerebrovascular disease, was associated with long-term statin exposure (p < 0.035). No significant associations were identified between long-term statin exposure and cerebral amyloid or tau burden, AD pattern neurodegeneration, or white matter hyperintensity burden. Conclusion: Long-term statin therapy was not associated with differences in AD biomarkers. Individuals with long-term statin exposure had worse white matter integrity in the genu of the corpus callosum, consistent with the coexistence of higher cerebrovascular risk factor burden in this group.

Original languageEnglish (US)
Pages (from-to)1345-1352
Number of pages8
JournalJournal of Alzheimer's Disease
Volume65
Issue number4
DOIs
StatePublished - Jan 1 2018

Fingerprint

Cerebrovascular Disorders
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Alzheimer Disease
Biomarkers
Health
Brain
Corpus Callosum
Neuroimaging
Anisotropy
Amyloid
Longitudinal Studies
Dementia
Cardiovascular Diseases
Prospective Studies
Therapeutics

Keywords

  • Alzheimer's disease
  • amyloid
  • biomarkers
  • cerebrovascular disease
  • magnetic resonance imaging
  • neurodegeneration
  • positron emission tomography
  • statins
  • tau
  • white matter

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Statins and Brain Health : Alzheimer's Disease and Cerebrovascular Disease Biomarkers in Older Adults. / Ramanan, Vijay K.; Przybelski, Scott A.; Graff-Radford, Jonathan; Castillo, Anna M.; Lowe, Val; Mielke, Michelle M; Roberts, Rosebud O; Reid, Robert I.; Knopman, David S; Jack, Clifford R Jr.; Petersen, Ronald Carl; Vemuri, Prashanthi D.

In: Journal of Alzheimer's Disease, Vol. 65, No. 4, 01.01.2018, p. 1345-1352.

Research output: Contribution to journalArticle

@article{53ad51351b6d4d36ab6dd88c7e7653be,
title = "Statins and Brain Health: Alzheimer's Disease and Cerebrovascular Disease Biomarkers in Older Adults",
abstract = "Background: Statins have been proposed to reduce the risk of Alzheimer's disease (AD). Objective: Assess whether long-term statin use was associated with neuroimaging biomarkers of aging and dementia. Methods: We analyzed neuroimaging biomarkers in 1,160 individuals aged 65+ from the Mayo Clinic Study of Aging, a population-based prospective longitudinal study of cognitive aging. Results: Statin-treated (5+ years of therapy) individuals had greater burden of mid-and late-life cardiovascular disease (p < 0.001) than statin-untreated (=3 months) individuals. Lower fractional anisotropy in the genu of the corpus callosum, an early marker of cerebrovascular disease, was associated with long-term statin exposure (p < 0.035). No significant associations were identified between long-term statin exposure and cerebral amyloid or tau burden, AD pattern neurodegeneration, or white matter hyperintensity burden. Conclusion: Long-term statin therapy was not associated with differences in AD biomarkers. Individuals with long-term statin exposure had worse white matter integrity in the genu of the corpus callosum, consistent with the coexistence of higher cerebrovascular risk factor burden in this group.",
keywords = "Alzheimer's disease, amyloid, biomarkers, cerebrovascular disease, magnetic resonance imaging, neurodegeneration, positron emission tomography, statins, tau, white matter",
author = "Ramanan, {Vijay K.} and Przybelski, {Scott A.} and Jonathan Graff-Radford and Castillo, {Anna M.} and Val Lowe and Mielke, {Michelle M} and Roberts, {Rosebud O} and Reid, {Robert I.} and Knopman, {David S} and Jack, {Clifford R Jr.} and Petersen, {Ronald Carl} and Vemuri, {Prashanthi D}",
year = "2018",
month = "1",
day = "1",
doi = "10.3233/JAD-180446",
language = "English (US)",
volume = "65",
pages = "1345--1352",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "4",

}

TY - JOUR

T1 - Statins and Brain Health

T2 - Alzheimer's Disease and Cerebrovascular Disease Biomarkers in Older Adults

AU - Ramanan, Vijay K.

AU - Przybelski, Scott A.

AU - Graff-Radford, Jonathan

AU - Castillo, Anna M.

AU - Lowe, Val

AU - Mielke, Michelle M

AU - Roberts, Rosebud O

AU - Reid, Robert I.

AU - Knopman, David S

AU - Jack, Clifford R Jr.

AU - Petersen, Ronald Carl

AU - Vemuri, Prashanthi D

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Statins have been proposed to reduce the risk of Alzheimer's disease (AD). Objective: Assess whether long-term statin use was associated with neuroimaging biomarkers of aging and dementia. Methods: We analyzed neuroimaging biomarkers in 1,160 individuals aged 65+ from the Mayo Clinic Study of Aging, a population-based prospective longitudinal study of cognitive aging. Results: Statin-treated (5+ years of therapy) individuals had greater burden of mid-and late-life cardiovascular disease (p < 0.001) than statin-untreated (=3 months) individuals. Lower fractional anisotropy in the genu of the corpus callosum, an early marker of cerebrovascular disease, was associated with long-term statin exposure (p < 0.035). No significant associations were identified between long-term statin exposure and cerebral amyloid or tau burden, AD pattern neurodegeneration, or white matter hyperintensity burden. Conclusion: Long-term statin therapy was not associated with differences in AD biomarkers. Individuals with long-term statin exposure had worse white matter integrity in the genu of the corpus callosum, consistent with the coexistence of higher cerebrovascular risk factor burden in this group.

AB - Background: Statins have been proposed to reduce the risk of Alzheimer's disease (AD). Objective: Assess whether long-term statin use was associated with neuroimaging biomarkers of aging and dementia. Methods: We analyzed neuroimaging biomarkers in 1,160 individuals aged 65+ from the Mayo Clinic Study of Aging, a population-based prospective longitudinal study of cognitive aging. Results: Statin-treated (5+ years of therapy) individuals had greater burden of mid-and late-life cardiovascular disease (p < 0.001) than statin-untreated (=3 months) individuals. Lower fractional anisotropy in the genu of the corpus callosum, an early marker of cerebrovascular disease, was associated with long-term statin exposure (p < 0.035). No significant associations were identified between long-term statin exposure and cerebral amyloid or tau burden, AD pattern neurodegeneration, or white matter hyperintensity burden. Conclusion: Long-term statin therapy was not associated with differences in AD biomarkers. Individuals with long-term statin exposure had worse white matter integrity in the genu of the corpus callosum, consistent with the coexistence of higher cerebrovascular risk factor burden in this group.

KW - Alzheimer's disease

KW - amyloid

KW - biomarkers

KW - cerebrovascular disease

KW - magnetic resonance imaging

KW - neurodegeneration

KW - positron emission tomography

KW - statins

KW - tau

KW - white matter

UR - http://www.scopus.com/inward/record.url?scp=85054132077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054132077&partnerID=8YFLogxK

U2 - 10.3233/JAD-180446

DO - 10.3233/JAD-180446

M3 - Article

VL - 65

SP - 1345

EP - 1352

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 4

ER -